The recent findings of eye disorders reported during clinical studies with different CDK inhibitors leading to clinical holds 1,2 have raised various questions:
- Is ocular toxicity a class effect of CDK inhibitors?
- Have ocular disorders been reported with already marketed CDK inhibitors?
- Were these toxicities anticipated in preclinical studies performed with different CDK inhibitors?
- Is the inhibition of all CDK subtypes associated with this safety liability or does evidence suggest a particular member(s) of the family to be the culprit?
Download the case study to find out how OFF-X™ can help answer these questions.
